Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Liposomal Doxorubicin and Docetaxel in Metastatic Breast Cancer

This study has been completed.
Information provided by:
First received: September 3, 2007
Last updated: June 29, 2011
Last verified: June 2011
Evaluation of safety and efficacy of a treatment associating Pegylated Liposomal Doxorubicin + Docetaxel in patients with metastatic breast cancer

Condition Intervention Phase
Metastatic Breast Cancer
Drug: Pegylated liposomal doxorubicin
Drug: Docetaxel
Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Multi-center Phase II Study Evaluating the Efficacy and Tolerance of the Association of Liposomal Doxorubicin and Docetaxel in First Line Chemotherapy in Patients With Metastatic Breast Cancer

Resource links provided by NLM:

Further study details as provided by ARCAGY/ GINECO GROUP:

Primary Outcome Measures:
  • Non-progression rate after 6 cycles [ Time Frame: 6 months ]

Secondary Outcome Measures:
  • tolerance and toxicity [ Time Frame: 6 months ]
  • Tumor response and duration [ Time Frame: 5 years ]
  • Time to Progression [ Time Frame: 5 years ]
  • Overall survival [ Time Frame: 5 years ]

Enrollment: 67
Study Start Date: February 2004
Study Completion Date: June 2009
Primary Completion Date: June 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Caelyx - Taxotere Drug: Pegylated liposomal doxorubicin
Caelyx 30 mg/m² day 1 every 3 weeks
Other Name: Caelyx
Drug: Docetaxel
Taxotere 75 mg/m² day 2 every 3 weeks
Other Name: Taxotere

Detailed Description:
Evaluation of safety and efficacy of a treatment associating Pegylated Liposomal Doxorubicin + Docetaxel in patients with metastatic breast cancer. Patients will receive pyridoxin to prevent cutaneo-mucinous toxicities.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • first metastatic chemo line
  • presence of measurable or bone lesion
  • at least one lesion outside the radiated areas
  • can have previously received hormonotherapy, chemotherapy in adjuvant phase, radiotherapy if older than 4 weeks

Exclusion Criteria:

  • only local tumoral progression
  • symptomatic cerebral metastasis
  • neuropathy > NCI-CTC 2
  • previous cancer within 10 years _ previous cancer within 10 years
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00524810

Paris, France, 75004
Sponsors and Collaborators
Principal Investigator: Laure CHAUVENET, MD, PHD Hôpital HOTEL DIEU - Paris
  More Information

Responsible Party: Douglas Micheau, ARCAGY-GINECO Identifier: NCT00524810     History of Changes
Other Study ID Numbers: CAPYTTOLE
Study First Received: September 3, 2007
Last Updated: June 29, 2011

Additional relevant MeSH terms:
Breast Neoplasms
Neoplasms by Site
Breast Diseases
Skin Diseases
Liposomal doxorubicin
Antibiotics, Antineoplastic
Antineoplastic Agents
Topoisomerase II Inhibitors
Topoisomerase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators processed this record on May 25, 2017